Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG – Get Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 67,279 shares, a growth of 1,315.5% from the June 15th total of 4,753 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average trading volume of 201,808 shares, the short-interest ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Get Bone Biologics alerts:

Get Our Latest Analysis on Bone Biologics

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its position in Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is currently owned by hedge funds and other institutional investors.

Bone Biologics Trading Up 0.7%

NASDAQ BBLG traded up $0.01 during trading hours on Friday, reaching $1.39. 24,135 shares of the company traded hands, compared to its average volume of 143,856. The stock has a market capitalization of $2.50 million, a PE ratio of -0.61 and a beta of 0.90. Bone Biologics has a 12 month low of $1.05 and a 12 month high of $4.13. The company has a 50 day moving average of $1.32 and a two-hundred day moving average of $1.37.

Bone Biologics (NASDAQ:BBLG – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). On average, equities research analysts anticipate that Bone Biologics will post -1.17 earnings per share for the current year.

Bone Biologics Company Profile

(Get Free Report)

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.

Featured Stories

• Five stocks we like better than Bone Biologics
• 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
• Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
• Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
• This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.